Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moFULVESTRANT (fulvestrant) by Chia Tai TianQing Pharmaceutical Group is estrogen receptor antagonists [moa]. Approved for breast cancer. First approved in 2020.
Drug data last refreshed 9h ago
Estrogen Receptor Antagonists
Estrogen Receptor Antagonist
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Worked on FULVESTRANT at Chia Tai TianQing Pharmaceutical Group? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo